Posted on October 29, 2014 by Sitemaster
Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AdV-tk, immunotherapy, localized, radiation, trial | 1 Comment »
Posted on May 23, 2011 by Sitemaster
A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer. … READ MORE …
Filed under: Drugs in development, Management | Tagged: AdV-tk, gene suicide, immunotherapy, localized, ProstAtak, vaccine, valacyclovir | Leave a comment »
